Shares of Ocular Therapeutix (OCUL) plummeted 10.69% in pre-market trading on Tuesday following the release of its disappointing second-quarter 2025 financial results. The biopharmaceutical company, focused on developing therapies for eye diseases, reported wider losses and a significant year-over-year revenue decline, causing investor concern.

Ocular Therapeutix reported a quarterly loss of $0.39 per share, missing analyst consensus estimates of $0.35 and representing a 50% increase in losses compared to the same period last year. The company's total net revenue for Q2 2025 came in at $13.5 million, an 18.1% decrease from the $16.4 million reported in the same quarter of the previous year. This decline was attributed to a challenging reimbursement environment for DEXTENZA, the company's flagship product, despite a 5% increase in DEXTENZA end-user unit sales.

Despite the disappointing financial results, Ocular Therapeutix highlighted some positive developments. The company reported a strong cash position of $391 million as of June 30, 2025, which is expected to support its planned expenses and capital expenditure requirements into 2028. Additionally, the company emphasized continued progress in its clinical trials, with the AXPAXLI™ SOL-1 trial for wet AMD on track for topline data in the first quarter of 2026. However, these long-term prospects were overshadowed by the immediate financial underperformance, leading to the significant pre-market drop in share price.